Scarica l'app Stockscreener
91.97
9.16%
-8.065
Precedente Chiudi:
$100.04
Aprire:
$92.82
Volume 24 ore:
651.26K
Relative Volume:
0.82
Capitalizzazione di mercato:
$5.27B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-31.07
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
-12.30%
1M Prestazione:
-16.74%
6M Prestazione:
-28.33%
1 anno Prestazione:
-3.64%
Intervallo 1D:
$88.75
$95.38
Intervallo di 1 settimana:
$88.75
$102.76
Portata 52W:
$88.75
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
91.87 | 5.27B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
132.06 | 229.74B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
98.88 | 145.53B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
362.76 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.84 | 114.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.97 | 42.24B | 5.72B | 4.17B | 259.90M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Glaukos stock touches 52-week low at $91.65 amid market shifts - Investing.com Australia
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Learn to Evaluate (GKOS) using the Charts - news.stocktradersdaily.com
Glaukos CFO Thurman Alex R. sells $162k in stock By Investing.com - Investing.com South Africa
Glaukos CFO Thurman Alex R. sells $162k in stock - Investing.com
Glaukos Corporation (NYSE:GKOS) Is Expected To Breakeven In The Near Future - simplywall.st
Breakeven On The Horizon For Glaukos Corporation (NYSE:GKOS) - Yahoo Finance
Primecap Management Co. CA Has $182.08 Million Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
First Week of May 16th Options Trading For Glaukos (GKOS) - Nasdaq
(GKOS) Trading Report - Stock Traders Daily
Glaukos, RadiusXR, and Topcon Healthcare Work to Advance Vision Testing - Medical Product Outsourcing
RadiusXR and Glaukos Announce a New Collaboration With Topcon Healthcare, Inc., and the Launch of Inspire - Vision Monday
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
Glaukos Licenses Iveena’s Investigational Keratoconus Therapy - Business Wire
Midday Stock Roundup: Xponential Fitness Plunges 38%, GEN Restaurant Group Up 10% - Orange County Business Journal
Glaukos Highlights Strategic Focus in 2024 Presentation - TipRanks
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution - 01Net
Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platform - TipRanks
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing - Stock Titan
Where are the Opportunities in (GKOS) - news.stocktradersdaily.com
US Bancorp DE Acquires 470 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
Glaukos Co. (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Glaukos Corp. to Host Earnings Call - ACCESS Newswire
289 Shares in Glaukos Co. (NYSE:GKOS) Bought by IFP Advisors Inc - Defense World
Bank of New York Mellon Corp Increases Holdings in Glaukos Co. (NYSE:GKOS) - Defense World
Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? - Insider Monkey
Glaukos, Tarsus, RxSight: Q4 Earnings Snapshot - Orange County Business Journal
Stifel maintains Buy on Glaukos stock, reiterates $175 target By Investing.com - Investing.com South Africa
Stifel maintains Buy on Glaukos stock, reiterates $175 target - Investing.com
Truist Financial Corp Sells 5,319 Shares of Glaukos Co. (NYSE:GKOS) - Defense World
7 Best Medical Technology Stocks To Buy According To Analysts - Insider Monkey
Glaukos CEO Makes a Multi-Million Dollar Stock Sale! - TipRanks
Glaukos director Mark Foley sells common stock for $2.5 million By Investing.com - Investing.com Australia
Glaukos director Mark Foley sells common stock for $2.5 million - Investing.com
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock? - MSN
Glaukos Corporation (NYSE:GKOS) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - Simply Wall St
(GKOS) Investment Report - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Sold by Taylor Frigon Capital Management LLC - MarketBeat
FDA accepts Glaukos application for Epioxa for keratoconus - MSN
CIBC Asset Management Inc Makes New Investment in Glaukos Co. (NYSE:GKOS) - Defense World
Needham & Company LLC Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
GLAUKOS Corp SEC 10-K Report - TradingView
FDA sets review date for Glaukos’ keratoconus drug By Investing.com - Investing.com Australia
GKOSGlaukos Corp Latest Stock News & Market Updates - StockTitan
FDA gives Glaukos ‘Day 74’ notice for Epioxa NDA to treat keratoconus - TipRanks
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Benzinga India
Glaukos Announces FDA Acceptance Of NDA Submission For Epioxa(TM) -February 24, 2025 at 08:24 am EST - Marketscreener.com
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™ - BioSpace
FDA sets review date for Glaukos' keratoconus drug - Investing.com India
Glaukos's Corneal Disease Drug Accepted for FDA Review -February 24, 2025 at 07:33 am EST - Marketscreener.com
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.62%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):